(Q80130954)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18052627%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

editorial

0 references

title

[Advances in cervical cancer prevention: HPV vaccines] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18052627%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

cervix uterine cancer

1 reference

Francesc Xavier Bosch José

inferred from title

author

series ordinal

2

object named as

F X Bosch

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18052627%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

X Castellsagué

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18052627%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 September 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18052627%20AND%20SRC:MED&resulttype=core&format=json

Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria

28 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18052627%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18052627%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18052627%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

261-263

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18052627%20AND%20SRC:MED&resulttype=core&format=json

The causal relation between human papillomavirus and cervical cancer

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975388-6

7 January 2021

Chapter 1: HPV in the etiology of human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975388-6

7 January 2021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975388-6

7 January 2021

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975388-6

7 January 2021

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975388-6

7 January 2021

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975388-6

7 January 2021

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975388-6

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975388-6

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975388-6

7 January 2021

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975388-6

7 January 2021

10.1016/S1130-6343(07)75388-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18052627%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference